200,000+ products from a single source!

sales@angenechem.com

Home > Each intermediate was followed by online FT- IR analysis of characteristic signals

Each intermediate was followed by online FT- IR analysis of characteristic signals

As expected, with the serial dilution that occurs on the stepwise addition of each reagent, the adiabatic temperature rise of each consecutive step decreases. Of particular note, however, is the very high adiabatic temperature rise of 110 °C following the n- butyl lithium addition. During this experiment, the concentration profile of each intermediate was followed by online FT- IR analysis of characteristic signals, Figure 3. A complete overview of the trending concentrations could be obtained, which was particularly pleasing since few, if any, of these intermediates were expected to be stable enough to be obtained as isolated analytical references.


In order to render the data acquired by FT-IR quantitative, off-line 1H NMR was also used to track key intermediates and byproducts. Once the mol % at a particular time point could be determined by NMR with an internal standard, the peak height by FT-IR could be correlated to this concentration at the same time point. In this way, the continuous data stream coming from the noninvasive FT-IR could be used to build a kinetic model of the reaction progress at a variety of temperatures and concentrations. Particularly insightful was the plot shown in Figure 4 which depicts the dose-controlled transition from compound 6 to compound 7. We determined that, at the slow dosing rate of n-butyl lithium in this experiment, both reactions were addition-controlled, but the rate of conversion of 6 into 6a had to be much faster than that for 6a to 7 in order to account for the sharp transitions observed in the concentration profiles of 6a and 7. As such the first equivalent of n-butyl lithium was almost entirely being employed in deprotonation of 6 to 6a, with very little being made available for ring closure of 6a to 7 (via ortho-lithiation and aryne formation).

 

In order to explore deviation scenarios, we devised an NMR experiment where dosing of n-butyl lithium was significantly faster and a local hot spot was certain to exist. At a faster dosing rate, we reasoned that we might shift away from a purely dose- controlled addition and begin to accumulate n-butyl lithium which could then be employed for not only selective deprotonation of 6 to 6a but also a parallel ring closure from 6a to 7. This would put lithiated benzoxazole 7 in the presence of starting material 6, a situation that we expected to compromise the selectivity of the reaction due to proton transfer between the acidic 6 and basic 7.15 The half amount of
n-butyl lithium (1.05 instead of 2.10 equiv) was added quickly to the starting material at −35 °C and a sample quenched with deuterated methanol at various time points. Figure 5 shows the 1H NMR spectra at 0.5 and 2.5 h where lithiated starting material 6a, lithiated benzoxazole 7, and other compounds can be identified as deuterium-quenched species (compound 6 could not be tracked by NMR due to background deuterium exchange of the acid NH proton). At 0.5 h (Figure 5a) compound 6a was the predominant product as expected, but already present was 10% of compound 7 which had evidently formed in parallel due to non-dose-controlled conditions brought about by accumulation of n-butyl lithium. Since a 9:1 ratio of 6a to 7 was integrated, by subtraction this required that residual starting material 6 was still present in an approximately 5% amount to account for the 1.05 equiv of n-butyl lithium initially added (otherwise a ratio of 10.0:0.5 of 6a to 7 would have been observed if all 6 had been consumed). By 2.5 h, Figure 5b, the newly identified proton-quench byproduct 10 had appeared in a 1:1 ratio with cyclized compound 7, as would be expected by the complete proton transfer from residual starting material 6 (initially 5%) to compound 7 (reduced now from 10 to 5%), with Figure 5c showing reference spectra of the proton-quenched byproduct 10 prepared separately. Based on this NMR study we concluded that if the chemistry was conducted under conditions where there was the coexistence of compounds 6 and 7 we would always generate byproduct 10 by proton transfer if sufficient time was given.16 In this way, we determined that a slow dosing rate would be a critical parameter if we wanted to avoid a local-zone effect, i.e. an accumulation of n-butyl lithium in the dosage area in batch. This was certainly a compatible criterion for the batch equipment which would otherwise reliably generate a  hot spot in the dosage area based on the calorimetry data outlined above.

 

Regarding the stability of compound 7, similar NMR experiments with a slower dosing of 2.1 equiv of n-butyl lithium (i.e., seeking to eliminate the possible presence of residual starting material 6 in the presence of lithiated 7, even during the dosing period) demonstrated that at −15 °C the lithiated intermediate 7 could be held for up to 1.5 h without significant degradation. However, if the temperature was raised to 0 °C then up to 70 mol % of a new byproduct identified as dimeric 11 was formed within 1.5 h, Table 1. The data strongly suggested that dimeric 11 was being formed from the desired intermediate 7 at this temperature.17 In complement, FT-IR tracking at three temperatures (10, 0, and −10 °C) confirmed the temperature sensitivity, and the kinetic data were used to set a maximal internal temperature of −10 °C for the ideal process.

 

In conclusion to these mechanistic studies, we took the NMR and FT-IR data together and realized that in order to retain the high purity of lithiated intermediate 7 the ideal process would require a long n-butyl lithium dosing time and good mixing to avoid a local-zone effect and the resulting issues of proton transfer from residual 6, as well as hot spots. However, the holding time of 7 should be as short as possible to avoid decomposition in general and dimerization to 11 in particular.


Our conclusion was that this paradoxical situation excluded the possibility of using batch equipment on manufacturing scale since a long dosing time would equate to a long holding time of 7 during dosing, and the mixing efficiency of large batch reactors was expected to decrease on increasing volume. In flow equipment, the dosing time is quasi-equivalent to the mixing time and can be rapid with judicious choice of flow rates and mixer type. Heat removal can also be excellent due to the higher surface-area-to-volume ratio compared to batch. Finally, the holding time of 7 could also be short in continuous flow since the next reagent would intercept the reaction mixture after a short time defined by the flow rates and volume of the selected equipment. The combination of calorimetry, FT-IR, and NMR studies therefore consistently pointed us toward carefully designed continuous flow equipment to handle the first step of the sequence toward compound 1.
NMR-based stability experiments on the lithium sulfinate 8 resulting from sulfur dioxide quench showed that it was entirely stable at the low temperature required for the ortho-lithiation. The first signs of decomposition according to SITARAM calorimetry began at 97 °C. Equally, sulfonyl chloride 9 was found to be stable in the reaction medium, with NMR holding experiments at room temperature over 3 days showing no sign of degradation. Background hydrolysis of 9 by the aqueous solution of the Weinreb amine was to be expected, however, and screening of the base required to deprotonate the Weinreb amine salt (vide supra) had already led us to select dipotassium hydrogen phosphate. Further inorganic carbonate and phosphate bases were included in the extended screening, but dipotassium hydrogen phosphate led to the least decomposition of compound 9 over an extended period at 30 °C according to quantitative HPLC, Table 2.
Sulfonyl chloride 9 was found to hydrolyze to the sulfonic acid only at elevated pH. Conversely, low pH led to ring-opening hydrolysis of the oxazole moiety in compound 1 to provide a phenolic compound. As such we avoided extreme acidity or basicity by only dosing 40% of the full 10 equiv of aqueous dipotassium hydrogen phosphate solution to the sulfonyl chloride, the remaining 60% coming premixed with the Weinreb amine in aqueous solution.

 

Having determined the kinetics for each of the byproduct pathways, summarized in Figure 6, these pathways were incorporated into the Dynochem-based kinetic model to enable an overall simulation of the reaction within the flow reactor equipment (see the Supporting Information).

 

In order to effectively select the appropriate flow reactor, we needed to tackle the issue of solid-generation which had been a critical issue on lab scale. Lithium chloride is a prime suspect as a precipitant in all chemistries between organolithium reagents and chloro-aromatics. Commercial solutions of lithium chloride are available at 0.5 M in tetrahydrofuran, and the maximum possible concentration in our chemistry was calculated at 0.3 M (1.0 equiv). However, since our solution contained dissolved substrates, and we operated at sub-ambient temperatures, we initiated a seeding experiment to determine if we were operating under conditions of supersaturation. Small, but successive amounts of lithium chloride (0.03 eq. then 0.04 equiv) were spiked into the mixture of starting material 6 and n-butyl lithium at −30 °C, but gratifyingly no crystallization event was observed over a 2 h aging period.19

 

Lithium sulfinate intermediate 8 is a known solid, and so as a next step, we prepared it in a separate experiment and recirculated a concentrated suspension by peristaltic pump between two glass vessels with a gravity overflow between them.20 Over 24 h no accumulation of solids at the bottom of the vessels or at the overflow junction was observed.

Over 100,000 products now available from Angene:

CAS No. 114275-39-7

1,3-Dioxan-5-ol, 4-(1E)-1-pentadecen-1-yl-2-phenyl-, (2S,4R,5R)-

Catalog No.:AG000AZ2 MDL No.:

MF:C25H40O3 MW:388.5833

CAS No. 114275-41-1

Propanoic acid, 2,2-dimethyl-, 2-azido-3-hydroxy-4-octadecenyl ester, [R-[R*,S*-(E)]]- (9CI)

Catalog No.:AG000AZ1 MDL No.:

MF: MW:

CAS No. 114275-42-2

Propanoic acid, 2,2-dimethyl-, 2-azido-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-octadecenyl ester, [R-[R*,S*-(E)]]- (9CI)

Catalog No.:AG000AZ0 MDL No.:

MF: MW:

CAS No. 114281-19-5

L-Glutamamide, 5-oxo-L-prolylglycyl-L-methionyl-L-isoleucylglycyl-L-threonyl-L-leucyl-L-threonyl-L-seryl-L-lysyl-L-arginyl-L-isoleucyl-L-lysyl-

Catalog No.:AG000AYZ MDL No.:

MF:C66H119N21O19S MW:1542.8454

CAS No. 114281-40-2

Piperidinium, 1-(4-amino-4-oxo-3,3-diphenylbutyl)-1-ethyl-, bromide (1:1)

Catalog No.:AG000AYY MDL No.:

MF:C23H31BrN2O MW:431.4090

CAS No. 114282-28-9

2-Furanmethanimine, N-nitro- (9CI)

Catalog No.:AG000AYX MDL No.:

MF:C5H4N2O3 MW:140.0969

CAS No. 114288-74-3

1,3-Oxathiane, 5,6-dimethyl-

Catalog No.:AG000AZR MDL No.:

MF:C6H12OS MW:132.2239

CAS No. 114288-80-1

Benzene, 1,1',1'',1'''-(1,4-dinitro-1,2,3,4-butanetetrayl)tetrakis- (9CI)

Catalog No.:AG000AZQ MDL No.:

MF:C28H24N2O4 MW:452.5012

CAS No. 114289-15-5

Phenol, 3-(3-methylbutyl)-5-(2-methylpropyl)-

Catalog No.:AG000AZP MDL No.:

MF:C15H24O MW:220.3505

CAS No. 114289-16-6

1H-Imidazole, 2-dodecyl-1-ethyl-4,5-dihydro-

Catalog No.:AG000AZO MDL No.:

MF:C17H34N2 MW:266.4653

CAS No. 114289-18-8

1,2-Ethanediamine, N1-(2-aminoethyl)-N2-[1-(1-piperazinyl)ethyl]-

Catalog No.:AG000AZN MDL No.:

MF:C10H25N5 MW:215.3390

CAS No. 114289-19-9

3-Furancarboxylic acid, 5,5-diethyl-4,5-dihydro-2,4-diphenyl-

Catalog No.:AG000AZM MDL No.:

MF:C21H22O3 MW:322.3976

CAS No. 114289-39-3

Dodecanamide, N-(2,6-dimethylphenyl)-2,2-dimethyl-

Catalog No.:AG000AZL MDL No.:

MF:C22H37NO MW:331.5353

CAS No. 114289-47-3

Dodecanamide, 2,2-dimethyl-N-(2,4,6-trimethoxyphenyl)-

Catalog No.:AG000AZK MDL No.:

MF:C23H39NO4 MW:393.5601

CAS No. 114289-76-8

Propanedioic acid, 2-methyl-2-tetradecyl-

Catalog No.:AG000AZJ MDL No.:

MF:C18H34O4 MW:314.4602

CAS No. 114289-77-9

Phenol, 2-(1,1-dimethylethyl)-4-(3-hydroxypropoxy)-

Catalog No.:AG000AZI MDL No.:

MF:C13H20O3 MW:224.2961

CAS No. 114289-85-9

2-Propene-1,2-diol, 3-(1,3-benzodioxol-5-yl)-

Catalog No.:AG000AZH MDL No.:

MF:C10H10O4 MW:194.1840

CAS No. 114289-96-2

1,3-Isobenzofurandione, 4,5-bis(dimethylamino)-

Catalog No.:AG000AZG MDL No.:

MF:C12H14N2O3 MW:234.2512

CAS No. 114289-97-3

Silane, bis(4-chlorophenyl)[(2-nitrophenyl)methoxy]- (9CI)

Catalog No.:AG000AZF MDL No.:

MF:C19H15Cl2NO3Si MW:404.3188

CAS No. 114290-34-5

3H-Xanthen-3-one, 2,6,7-trihydroxy-9-undecyl-

Catalog No.:AG000AZE MDL No.:

MF:C24H30O5 MW:398.4920

CAS No. 114290-37-8

Benzamide, N-[2-(phenylseleno)cyclohexyl]-

Catalog No.:AG000AZD MDL No.:

MF:C19H21NOSe MW:358.3361

CAS No. 114290-38-9

Phosphonium, tributylhexadecyl-, acetate (9CI)

Catalog No.:AG000AZC MDL No.:

MF:C30H63O2P MW:486.7938

CAS No. 114290-53-8

Copper, fluoromethyl- (9CI)

Catalog No.:AG000AZB MDL No.:

MF:CH2CuF MW:96.5710

CAS No. 114290-60-7

Phenol, 2,4,6-tris[[(hydroxymethyl)methylamino]methyl]-

Catalog No.:AG000AZA MDL No.:

MF:C15H27N3O4 MW:313.3926

CAS No. 114290-69-6

Hexanedioic acid, 1-(7-oxabicyclo[4.1.0]hept-3-yl) 6-(7-oxabicyclo[4.1.0]hept-3-ylmethyl) ester

Catalog No.:AG000AZ9 MDL No.:

MF:C19H28O6 MW:352.4220

CAS No. 114290-87-8

Benzenamine, N,N'-1,4-cyclohexanediylidenebis- (9CI)

Catalog No.:AG000AZ8 MDL No.:

MF:C18H18N2 MW:262.3489

CAS No. 114291-16-6

3-Pyridinesulfonamide, 5-chloro-6-hydrazinyl-

Catalog No.:AG000AZ7 MDL No.:

MF:C5H7ClN4O2S MW:222.6527

CAS No. 114291-42-8

2H-Pyran-2,4(3H)-dione, 3-(2,4-dichlorobenzoyl)-6-methyl-

Catalog No.:AG000AZ6 MDL No.:

MF:C13H8Cl2O4 MW:299.1062

CAS No. 114291-45-1

2H-Pyran-2,4(3H)-dione, dihydro-6-methyl-3-(2-nitrobenzoyl)-

Catalog No.:AG000AZ5 MDL No.:

MF:C13H11NO6 MW:277.2295

CAS No. 114291-63-3

2-Propenamide, 2-fluoro-N-(2-methylphenyl)-

Catalog No.:AG000AZ4 MDL No.:

MF:C10H10FNO MW:179.1909

CAS No. 114292-37-4

Thiophene, 3-ethoxy-

Catalog No.:AG000AZ3 MDL No.:

MF:C6H8OS MW:128.1921

CAS No. 114292-48-7

Benzene, 1-ethenyl-3-ethynyl-

Catalog No.:AG000B0G MDL No.:

MF:C10H8 MW:128.1705

CAS No. 114292-81-8

Benzene, 1,4-bis[2-[(1-methylethyl)phenyl]ethenyl]- (9CI)

Catalog No.:AG000B0F MDL No.:

MF:C28H30 MW:366.5378

CAS No. 114292-87-4

Naphthalene, bis(1-phenylethyl)- (9CI)

Catalog No.:AG000B0E MDL No.:

MF:C26H24 MW:336.4688

CAS No. 114292-89-6

Octanol, heptadecafluoro- (9CI)

Catalog No.:AG000B0D MDL No.:

MF:C8HF17O MW:436.0658

CAS No. 114292-91-0

Pyridinediamine, ar-bromo- (9CI)

Catalog No.:AG000B0C MDL No.:MFCD03427651

MF:C5H6BrN3 MW:188.0252

CAS No. 1142924-89-7

Benzene, 1-(1,1-difluoroethyl)-4-iodo-

Catalog No.:AG000B0A MDL No.:

MF:C8H7F2I MW:268.0425

CAS No. 1142925-09-4

3-Furancarboxylic acid, 2-amino-, ethyl ester

Catalog No.:AG000B09 MDL No.:

MF:C7H9NO3 MW:155.1513

CAS No. 1142927-36-3

1,5-Naphthyridine-2-carbonitrile

Catalog No.:AG000B08 MDL No.:MFCD18802347

MF:C9H5N3 MW:155.1561

CAS No. 1142927-37-4

1,5-Naphthyridine-3-carbonitrile

Catalog No.:AG000B07 MDL No.:MFCD18374128

MF:C9H5N3 MW:155.1561

CAS No. 1142927-95-4

4-Pyridazineacetonitrile

Catalog No.:AG000B06 MDL No.:MFCD17015867

MF:C6H5N3 MW:119.1240

CAS No. 114293-16-2

8-Octadecenedioic acid, 11-ethenyl-

Catalog No.:AG000B0B MDL No.:

MF:C20H34O4 MW:338.4816

CAS No. 1142944-51-1

Ethanamine, 2-[(4-bromo-2-pyridinyl)oxy]-N,N-diethyl-

Catalog No.:AG000B05 MDL No.:

MF:C11H17BrN2O MW:273.1695

CAS No. 1142944-58-8

Ethanamine, 2-[(4-bromo-2-pyridinyl)oxy]-N,N-dimethyl-

Catalog No.:AG000B04 MDL No.:

MF:C9H13BrN2O MW:245.1163

CAS No. 1142944-78-2

Boronic acid, B-(5-methoxy-2-pyridinyl)-

Catalog No.:AG000B03 MDL No.:MFCD08752653

MF:C6H8BNO3 MW:152.9436

CAS No. 1142945-81-0

Guanidine, N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, 2,2,2-trifluoroacetate (1:1)

Catalog No.:AG000B02 MDL No.:

MF:C15H21F3N4O3 MW:362.3474

CAS No. 1142945-82-1

4H-Pyrrolo[2,3-d]pyriMidin-4-one, 3,7-dihydro-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]aMino]-

Catalog No.:AG000B01 MDL No.:

MF:C18H21N5O2 MW:339.3916

CAS No. 1142945-83-2

7H-Pyrrolo[2,3-d]pyriMidin-2-aMine, 4-chloro-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-

Catalog No.:AG000B00 MDL No.:

MF:C18H20ClN5O MW:357.8373

CAS No. 1142945-86-5

7H-Pyrrolo[2,3-d]pyriMidine, 2-chloro-7-[(4-Methylphenyl)sulfonyl]-4-(4-Methyl-2-thienyl)-

Catalog No.:AG000AZZ MDL No.:

MF:C18H14ClN3O2S2 MW:403.9057

CAS No. 1142946-01-7

7H-Pyrrolo[2,3-d]pyriMidin-2-aMine, 4-(4-Methyl-2-thienyl)-N-[4-(4-MorpholinylMethyl)phenyl]-

Catalog No.:AG000AZY MDL No.:

MF:C22H23N5OS MW:405.5159

CAS No. 1142946-16-4

4H-Pyrrolo[2,3-d]pyriMidin-4-one, 3,7-dihydro-2-[[4-(4-Methyl-1-piperazinyl)phenyl]aMino]-

Catalog No.:AG000AZX MDL No.:

MF:C17H20N6O MW:324.3803

CAS No. 1142946-17-5

7H-Pyrrolo[2,3-d]pyriMidin-2-aMine, 4-chloro-N-[4-(4-Methyl-1-piperazinyl)phenyl]-

Catalog No.:AG000AZW MDL No.:

MF:C17H19ClN6 MW:342.8260

CAS No. 1142946-81-3

Boronic acid, B-(5-cyanobenzo[b]thien-2-yl)-

Catalog No.:AG000AZV MDL No.:MFCD15143421

MF:C9H6BNO2S MW:203.0254

CAS No. 1142947-79-2

4(3H)-PyriMidinone, 6-aMino-5-(2,2-diethoxyethyl)-2-[[3-(4-Methyl-1-piperazinyl)phenyl]aMino]-

Catalog No.:AG000AZU MDL No.:

MF:C21H32N6O3 MW:416.5172

CAS No. 1142947-80-5

4H-Pyrrolo[2,3-d]pyriMidin-4-one, 3,7-dihydro-2-[[3-(4-Methyl-1-piperazinyl)phenyl]aMino]-

Catalog No.:AG000AZT MDL No.:

MF:C17H20N6O MW:324.3803

CAS No. 1142947-81-6

7H-Pyrrolo[2,3-d]pyriMidin-2-aMine, 4-chloro-N-[3-(4-Methyl-1-piperazinyl)phenyl]-

Catalog No.:AG000AZS MDL No.:

MF:C17H19ClN6 MW:342.8260

CAS No. 1142953-55-6

1,4-Benzodioxin, 2-(bromomethyl)-2,3-dihydro-, (2R)-

Catalog No.:AG000B0H MDL No.:MFCD12756174

MF:C9H9BrO2 MW:229.0706

CAS No. 114299-64-8

4-Octadecen-1-ol, 2-azido-3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-, (2S,3R,4E)-

Catalog No.:AG000B0J MDL No.:

MF:C24H49N3O2Si MW:439.7503

© 2019 Angene International Limited. All rights Reserved.